Abstract CT130: Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors

Authors: Zev A. Wainberg, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Christine Burnett, Joshua Pelham, Eric T. Williams, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Brian A. Van Tine

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-ct130

Source: Full article